A variety of consultant options are available to the pharma industry; this article is a 3-step guide to selecting the right consultant.
The pharmaceutical industry is one that relies heavily on consulting support across the product journey. From new drug application (NDA) to loss of exclusivity (LOE), commercialization consulting options are abundant, but sometimes finding the right consultant can be a challenge.
One of the benefits of decades of experience is knowing what good-and bad-looks like and learning how to align your needs and expectations with the expertise, experience, and capabilities of the right consultant for your project.
Having been on both sides of the consulting relationship-as the client and as the consultant-we’ve learned a few things about how to select a consulting partner that is the right fit, right now.
1. Look in the mirror. Deeply.
Finding the best consultant for your unique needs starts with you. It’s important to clearly define your goals and identify the strengths and weaknesses in your team, capabilities, and capacity to know where consulting help is most needed and exactly what type of consulting support you need.
Ask these questions internally before you begin to engage with prospective consulting groups:
2. Put the consultants under the microscope.
Once your introspective work is done, you should have a much better idea of what kind of consulting help you need. When evaluating potential consultants you’ll want to keep this in mind, but be sure to look just as deeply at how they approach their client engagements to ensure a great fit.
Based on how you answered the above, ask potential consulting partners the appropriate version of these questions:
3. Before making your decision, consider these general guidelines.
A large consulting practice with a global footprint and diverse service offering may be the best fit for you if:
A smaller, specialized, boutique consulting group may be the best fit for you if:
Selecting the right consultant can have an enormous impact on the success of your project. As the importance of your project rises, so should the level of attention paid to selecting the best partner. Taking time to follow these three steps will help you to have confidence in your consultant and ensure the success of your project.
Keith Bailey, Director, US New Products at Novartis
Douglas Bock, Partner at Archbow Consulting.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.